Talha Badar: What we have learned about TP53-mutated AML?
Talha Badar, Hematology/Oncology specialist in Mayo Clinic, shared an article by Moazzam Shahzad on X:
“Happy to share our review: What we have learned about TP53-mutated AML?
Blood Cancer Journal Moazzam Shahzad Naval Daver Mohamed Kharfan-Dabaja Comprehensive review on (1) TP53 allelic burden and outcome, (2) TP53m MN in context to blast %, (3) Outcome with non-intensive vs intensive vs novel Rx (4) role of allo-HCT leusm.”
What have we learned about TP53-mutated acute myeloid leukemia?
Authors: Moazzam Shahzad, et al.
Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023